CTIS2023-506139-13-00招募中1 期
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS - XPORT-MF-034
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 304
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Spleen volume of =450 cm3 by MRI or CT scan., DIPSS risk category of intermediate-1, or intermediate-2, or high-risk., ECOG Performance Status =2., Platelet count =100 × 109/L without platelet transfusion., Active symptoms of MF as determined by presence of at least 2 symptoms with a score =3 or total score of =10 at screening using the MFSAF V4.0.
排除标准
- •Previous treatment with JAK inhibitors for MF., More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase).
研究者
相似试验
进行中（未招募）
1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864EUCTR2022-000073-12-HUPTC Therapeutics, Inc.345
招募中
1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864EUCTR2022-000073-12-PLPTC Therapeutics, Inc.345
进行中（未招募）
1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864EUCTR2022-000073-12-ESPTC Therapeutics, Inc.345
进行中（未招募）
1 期
A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMAeiomyosarcomaMedDRA version: 20.0Level: HLTClassification code 10024190Term: LeiomyosarcomasSystem Organ Class: 100000004864EUCTR2022-000073-12-FRPTC Therapeutics, Inc.345
尚未招募
2 期
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcomamalignant smooth muscle tumor10072990LeiomyosarcomaNL-OMON53907PTC Therapeutics, Inc.10